In western older, frailer advanced ESCC patients in the GO2 clinical trial (n = 32), worse median overall survival was observed in the high versus low IGF1R expression group [2.0 months (95% CI; 1.8–NA) versus 8.3 months (5.2–NA) (HR, 3.99; 95% CI 1.62–9.80, p = 0.003)], respectively (Fig. 3a). The gene discussed is IGF1R; the disease is esophageal squamous cell carcinoma.